TOKYO ( TheStreet) -- Astellas Pharma , the No. 2 drugmaker in Japan, reached an agreement to acquire OSI Pharmaceuticals ( OSIP) for $4 billion.

Astellas increased its offer for OSI to $57.50 a share, up from $52 the Japanese company had offered in March. The offer is a premium of 55% to the $37.02 closing price of OSI on Feb. 26, the last trading day Astellas announced its bid.

OSI shares closed Friday at $59.80.

OSI's drug line-up includes the blockbuster cancer drug Tarceva, which had $1.2 billion in sales in 2009.

"The merger with OSI provides Astellas with a top-tier oncology platform in the U.S. and an expanded product portfolio and pipelines," said Masafumi Nogimori, president and CEO of Astellas in a statement Monday.

-- Reported by Joseph Woelfel in New York.

Follow TheStreet.com on Twitter and become a fan on Facebook.

More from Stocks

Markets Look Confused After Latest Beating

Markets Look Confused After Latest Beating

General Electric Expulsion From Dow Symbolizes Unsettled Week in Markets

General Electric Expulsion From Dow Symbolizes Unsettled Week in Markets

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In